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Abstract
Objective To determine whether a systematic approach to the treatment
of pain can reduce agitation in people with moderate to severe dementia
living in nursing homes.
Design Cluster randomised controlled trial.
Setting 60 clusters (single independent nursing home units) in 18 nursing
homes within five municipalities of western Norway.
Participants 352 residents with moderate to severe dementia and
clinically significant behavioural disturbances randomised to a stepwise
protocol for the treatment of pain for eight weeks with additional follow-up
four weeks after the end of treatment (33 clusters; n=175) or to usual
treatment (control, 27 clusters; n=177).
Intervention Participants in the intervention group received individual
daily treatment of pain for eight weeks according to the stepwise protocol,
with paracetamol (acetaminophen), morphine, buprenorphine transdermal
patch, or pregabaline. The control group received usual treatment and
care.
Main outcome measures Primary outcome measure was agitation
(scores on Cohen-Mansfield agitation inventory). Secondary outcome
measures were aggression (scores on neuropsychiatric inventory-nursing
home version), pain (scores on
mobilisation-observation-behaviour-intensity-dementia-2), activities of
daily living, and cognition (mini-mental state examination).
Results Agitation was significantly reduced in the intervention group
compared with control group after eight weeks (repeated measures
analysis of covariance adjusting for baseline score, P<0.001): the
average reduction in scores for agitation was 17% (treatment effect
estimate −7.0, 95% confidence interval −3.7 to −10.3). Treatment of pain
was also significantly beneficial for the overall severity of neuropsychiatric
symptoms (−9.0, −5.5 to −12.6) and pain (−1.3, −0.8 to −1.7), but the
groups did not differ significantly for activities of daily living or cognition.
Conclusion A systematic approach to the management of pain
significantly reduced agitation in residents of nursing homes with
moderate to severe dementia. Effective management of pain can play
an important part in the treatment of agitation and could reduce the
number of unnecessary prescriptions for psychotropic drugs in this
population.
Trial registration ClinicalTrials.gov NCT01021696 and Norwegian
Medicines Agency EudraCTnr 2008-007490-20.
Introduction
Thirty five million people worldwide have dementia, and this
number is expected to increase to 115 million by 2050.
1
Agitationandaggressionarecommoninpeoplewithdementia,
in particular those with moderate to severe dementia living in
nursing homes, where the cross sectional prevalence of these
symptomsexceeds50%.
2 3Agitationisassociatedwithincreased
distress to residents and a burden to family and professional
caregivers
4 and is one of the most challenging symptoms for
clinical management.
Antipsychotics are often used as first line drug treatment for
agitation and aggression, with 40-60% of residents with
dementia in nursing homes prescribed such treatment.
5 In the
United Kingdom alone, a report for the Department of Health
estimated that 180 000 people with dementia were being
prescribedantipsychotics,causing1620excessstrokesand1800
deaths a year.
6 These figures emphasise the importance of
finding safe and effective ways to reduce agitation and
aggression in people with dementia.
Manypeoplewithdementiahavepainfulconditions,
7andithas
been proposed that pain in patients with impaired language and
abstractthinkingmaymanifestasagitation.
8Thusmoreeffective
treatment of undiagnosed pain may contribute to the overall
prevention and management of agitation. Overall, 50-80% of
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Research
RESEARCHresidents in nursing homes are affected by pain
9 and most good
practice guidelines emphasise the importance of pain
management in the treatment of neuropsychiatric symptoms in
people with dementia.
10 Few studies have, however, explored
the potential utility of treating pain as a way of improving
agitation.
11-14Weevaluatedwhethersystematicuseofanalgesics
canreduceagitationinresidentsofnursinghomeswithmoderate
to severe dementia.
Methods
DuringOctober2009toJune2010wecarriedoutamulticentre,
cluster randomised controlled trial for eight weeks, with an
additional follow-up at 12 weeks (four weeks after the end of
treatment) in 60 nursing home units within five municipalities
of western Norway. A cluster was defined as a single
independentnursinghomeunit(withnocrossoverofstaff).We
chose this design primarily to avoid contamination, because
care staff receiving training in the assessment and treatment of
paincannotbeexpectedtotreatindividualresidentsdifferently.
The study statistician (OBN) used Stata version 8 to generate
a list of random numbers for allocation of clusters to one of the
two groups.
Eligible participants were adults aged 65 or more, living in one
of the nursing homes for at least four weeks, with dementia
according to Diagnostic and Statistical Manual of Mental
Disorders, fourth edition, functional assessment staging score
ofmorethan4,andclinicallyrelevantbehaviouraldisturbances,
defined as a score of 39 or more on the Cohen-Mansfield
Agitation Inventory—that is, clinically significant agitation for
at least one week.
15 Exclusion criteria were advanced severe
medical disease with expected survival of less than six months,
severe psychiatric or neurological disorder, severe aggression
(agitation score ≥8 on the neuropsychiatric inventory-nursing
home version,
16 with aggression as the predominant symptom),
severe liver or renal failure, severe injury or anaemia
(haemoglobin concentration <8.5 mmol/L), and known allergy
to paracetamol (acetaminophen), morphine, buprenorphine, or
pregabaline.
Intervention
We randomly assigned patients to receive either treatment for
pain according to a stepwise protocol for eight weeks or their
usual management (the control group). The stepwise protocol
followed the recommendations of the American Geriatrics
Society.
17 Participants in the intervention group received
analgesics according to the standardised protocol. Depending
on the ongoing medical treatment, participants allocated to the
treatmentprotocolstartedatstep1(oralparacetamol,maximum
increase to 3 g/day) or, if they were already receiving treatment
were adjusted to either step 2 (oral morphine, maximum 20
mg/day), step 3 (buprenorphine transdermal patch, maximum
10 µg/h), or step 4 (oral pregabaline, maximum 300 mg/day),
usingafixeddoseregimenthroughouttheeightweektreatment
period. Residents with swallowing difficulties were started at
step3.Drugswereofferedatbreakfast,lunch,anddinner(about
08:00, noon, 18:00), respectively. If needed, combination
therapywasallowed.Inthosewhowerenotabletotoleratethis
treatment, the dosage was either reduced or the participant was
withdrawn from the study and treated as clinically appropriate.
Concomitant drugs
Anti-dementia drugs, psychotropics, aspirin (one dose daily),
or anti-inflammatory drugs (for example, ibuprofen) were
allowed if participants had remained stable on these for four
weeksbeforestudyinclusion.Weallowedtheuseofanalgesics
as needed (other than paracetamol) and monitored this during
the study. Clinicians were advised to keep prescriptions and
doses of psychotropics unchanged when possible.
Primary and secondary outcome measures
The primary outcome was agitation, as measured on the
Cohen-Mansfield agitation inventory, a nurses’ rating
questionnaire consisting of 29 agitated behaviours, each rated
on a 7 point scale of frequency (1=not present, 7=several times
an hour; range 29-203).
15 Secondary outcome measures were
aggression(neuropsychiatricinventory-nursinghomeversion),
16
pain
(mobilisation-observation-behaviour-intensity-dementia-2),
18
cognition (mini-mental state examination),
19 activities of daily
living,
20 and functional assessment staging. The
Cohen-Mansfield agitation inventory, neuropsychiatric
inventory-nursing home version, and
mobilisation-observation-behaviour-intensity-dementia-2 pain
scale were completed at baseline, at two, four, and eight weeks
after baseline, and at four weeks after the conclusion of
treatment. We evaluated cognition (mini-mental state
examination), activities of daily living, functional assessment
staging,anddrugsatbaselineandaftereightweeksoftreatment.
Procedures
After receiving specific training in use of the instruments two
research assistants carried out assessments by interviewing the
primary caregiver during enrolment. A consultant for old age
psychiatry (DA), an anaesthetist and pain therapist (BSH), one
of the research assistants (RS), and a senior member of staff
from each nursing home reviewed the outcomes of assessment
and drug prescriptions for each patient after completion of
baseline assessment but before randomisation.
Research assistants and caregivers were blinded to group
allocation during assessments of the primary and secondary
outcomes.Staffmembersindirectcarecontactwithparticipants
were unaware of the type of intervention. To ensure blindness,
researchers and nurses with responsibility for carrying out the
interventiondidnotparticipateindatacollection.Nursinghome
staff were instructed not to discuss management procedures.
Safety and tolerability were monitored at each assessment and
all adverse events and vital signs recorded.
Sample size
Based on the magnitude of improvement in randomised
controlled trials of non-drug interventions for agitation in
residents of nursing homes,
21 we estimated that a 25% greater
reduction of Cohen-Mansfield agitation inventory score in the
interventiongroupcomparedwithcontrolgroupwouldindicate
equivalence to the best currently available approaches. For
example, in a recent study we found that the largest
improvement for a psychosocial intervention was 7.1 points,
and thus a 25% difference would be about a 5 versus 7 point
improvement in the two groups.
22 To measure a difference of
thismagnitudewouldrequireaminimumof81patientsallocated
to each arm of the trial, for a significance level of 5% (two
sided), a power of 95%, and equal allocation.
Clusterrandomisationleadstolossofpower.
23Toretainpower,
the sample size should be multiplied by 1+(m−1)ρ, called the
design effect, where m is the average cluster size and
ρ=s
2
b/(s
2
b+s
2
w) is the intracluster correlation coefficient, where
s
2
bisthevariancebetweenclustersands
2
wisthevariancewithin
clusters. Based on additional assumption of an estimated
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RESEARCHintracluster correlation coefficient of 0.13, an average of seven
eligibleandconsentingparticipantsineachcluster,theformula
gives a design effect of 1.78 (1+(7−1)×0.13). Thus we
determined that we needed a minimum of 169.1 (1.78×95)
eligible participants per arm, which is in order of 26 clusters
per arm, or 52 clusters with 338 participants in total. To allow
for dropout of individual participants and loss of clusters, we
aimed at including 60 clusters.
Statistical analysis
We used χ
2 and Mann-Whitney tests as appropriate to compare
personal and clinical characteristics between the two groups.
Theanalysisofcovariancewasusedtoestimatethemeaneffect
in each treatment arm, weighted across clusters according to
the number of participants within each cluster, and from this
we obtained the mean treatment effect estimate (difference
betweengroups)ateachtimepoint.
24Theintraclustercorrelation
coefficient expressed the proportion of the total variance in the
dataduetothebetweenclustervariability.Theprimaryefficacy
population included all residents with at least one post-baseline
assessment,usingthelastobservationcarriedforwardprocedure
to account for missing values. Treatment effect was expressed
asestimatedeffectofintervention,alongwitha95%confidence
intervalandthePvaluesforeachtimepoint.Additionalanalyses
included repeated measurement analysis of covariance without
the last observation carried forward and comparison of change
at weeks 2, 4, and 8 using Student’s t test. We used the same
procedures to analyse the secondary outcome measures of pain
and aggression, whereas to analyse the effect on the secondary
outcomemeasuresofcognitionandactivitiesofdailylivingwe
used Student’s t test to compare the changes between baseline
and week 8 between the two treatment groups. Analyses were
carried out using predictive analytics software statistics 17
(SPSS; Chicago, IL).
Results
In total, 920 nursing homes residents were screened; 420 had
moderatetoseveredementiawithbehaviouraldisturbancesand
were assessed for eligibility. Sixty eight were excluded from
randomisation because they did not meet the inclusion criteria,
they declined to participate, or there were other reasons (fig 1).
Overall, 352 residents in 60 clusters underwent randomisation
(27 control clusters (n=177), 33 intervention clusters (n=175),
fig 1). The median number of participants in each cluster was
6.5 (range 2-11). The groups had similar personal and clinical
characteristics and outcome measures at baseline (table 1). In
all, 59% (n=103) of the intervention group and 55% (n=98) of
thecontrolgrouphadclinicallyrelevantpainscoresof3ormore
onthemobilisation-observation-behaviour-intensity-dementia-2
pain scale at baseline.
During the eight weeks 20 participants were lost in the control
group and 28 in the intervention group (P=0.298). Fourteen
participants died during the study period, eight in the control
group and six in the intervention group (fig 1).
Analgesics during intervention
Table 2 shows the distribution of treatments for pain. In the
intervention group, 111 (63%) participants received step 1
(paracetamol3g/day)ofthetreatmentprotocol,andinaddition
nine patients (5%) an existing low dosage was increased. Four
participants (2%) received step 2 (three started with morphine;
in one patient the primary prescription was adjusted). Thirty
one participants (18%) received step 3 (buprenorphine
transdermal patch), and in addition eight participants (5%) the
dosage was increased. Twelve participants (7%) received step
4 (pregabaline).
Outcome
Table 3 and figure 2 show the change in scores on the
Cohen-Mansfield agitation inventory in the two groups. The
repeated measurement analysis of covariance, using the
population with last observation carried forward, was
significantly different between the intervention and control
groupsaftereightweeks,infavourofpaintreatment(P<0.001):
the average reduction in agitation was 17% (treatment effect
estimate −7.0, 95% confidence interval −3.7 to −10.3). The
findings were similar when analysed based on only completers
(P<0.001), and the change from baseline differed between the
groups at weeks 2, 4, and 8. In the intervention group there was
a worsening of scores on the Cohen-Mansfield agitation
inventory between week 8 and week 12, after withdrawal of
pain treatment.
Between group differences in favour of pain treatment were
also significant for aggression (−9.0, −5.5 to −12.6) and pain
(−1.3, −0.8 to −1.7; tables 4 and 5). The correlation between
painandaggressionwassignificantatweek8(P=0.01).Atweek
8theinterventionandcontrolgroupsdidnotdiffersignificantly
for cognition (mini-mental state examination) (P=0.127; mean
7.4 and 8.6, respectively) or activities of daily living (P=0.443;
mean 7.9 and 8.4, respectively).
Discussion
A standardised stepwise protocol of treatment with analgesics
inresidentsofnursinghomeswithmoderatetoseveredementia
and agitation significantly improved agitation, overall
neuropsychiatricsymptoms,andpain.Thesefindingsemphasise
theimportanceofassessingandtreatingpaineffectivelyaspart
of the overall treatment and prevention of agitation and
aggression in patients with dementia. The results also highlight
the potential value of effective treatment of pain as a key part
of reducing the use of antipsychotics and other psychotropic
drugs in residents of nursing homes.
Thecurrentstudyisthefirstadequatelypoweredparallelgroup
randomisedcontrolledtrialofpainmanagementforthetreatment
of agitation in patients with moderate to severe dementia, and
thepositiveresponseissupportedbytheworseningofagitation
over the four weeks of follow-up after the intervention had
stopped. At the end of the intervention the groups differed by
7.0points,witha17%advantageovercontrolinthepercentage
change in score on the Cohen-Mansfield agitation inventory
over the duration of the trial. To put this into context, the three
studies using the Cohen-Mansfield agitation inventory as an
outcomeinrandomisedcontrolledtrialsofrisperidone(theonly
licensed drug treatment for agitation or aggression in people
with dementia) reported 3%, 13%, and 18% advantages
compared with placebo, respectively.
25-27 The clinical
significance of the benefit therefore compares well to the
currently best available drug therapy. The clinical relevance is
furthersupportedbythesignificantcorrelationobservedbetween
change in agitation and change in pain. The results from
previous open studies and case series are variable. A placebo
controlled study of 167 patients in nursing homes, providing
implementationofpersonalised,non-drugintervention,resulted
in decreased agitation in the intervention group,
21 but the
findings were not replicated in an open study of 114 residents
in nursing homes, which included pain management as part of
aprotocoltodealwithunmetneeds.
13Asubsequenttrialofpain
treatment with paracetamol (acetaminophen) in 25 residents in
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RESEARCHnursing homes reported an increase in general activities and
social interaction but no direct improvement in agitation.
12
Finally, a double blind crossover trial of pain treatment with
oxycodone and morphine in 47 residents in nursing homes,
improved agitation in older but not in younger patients and
showed a high frequency of dropouts.
14 These studies show
some support for the potential benefit of managing agitation by
treating unmet needs such as pain, but with considerable
differences in the type and magnitude of benefit, emphasising
the need for a robust randomised controlled trial.
11 The current,
adequately powered parallel group randomised controlled trial
shows more clear benefits. In clinical practice, by providing an
effective treatment approach for people with dementia and
agitation, improved management of pain should also help to
reduce the number of prescriptions for antipsychotics in this
population.
It is possible that agitation declined as a result of residents
receivingsedationwithopioidanalgesics.However,onlyafew
(25.6%) were treated with sedative agents (table 2), and few
residents (n=3) were excluded because of drowsiness and
nausea.Neitheractivitiesofdailylivingnorcognitionworsened
inthetreatmentgroupcomparedwithcontrolgroup,suggesting
that sedation could not explain the reduction of agitation in the
active group.
In this study, some behavioural symptoms improved in both
interventionandcontrolclusters.ThatmayindicateaHawthorne
effect,
28perhapsrelatedtofactorssuchasincreasedstafftraining
and support. Improvements in control groups is similar to other
studies investigating drug and non-drug treatments for
neuropsychiatric symptoms in people with dementia and is
consistent with the potential benefits of interventions such as
social interaction and reminiscence.
29 Precautions were taken
to blind research assistants and caregivers to group allocation,
but despite these efforts these studies will always be difficult
to fully blind because of the requirements in a nursing home
setting.
Importantly, in the current study, active intervention conferred
significantlygreaterbenefitsoverandabovenon-specificeffects.
The results highlight that a standardised approach to improved
pain management is a practical intervention that would be
straightforwardtoimplementwidelyforthebenefitofagitation
in residents of nursing homes with dementia.
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RESEARCHWhat is already known on this topic
Many people with dementia have painful conditions, which in people with impaired language and abstract thinking may
manifest as agitation
An estimated 180 000 people with dementia in the United Kingdom are prescribed antipsychotics for agitation
What this study adds
A standardised protocol to treat pain in residents of nursing homes with moderate to severe dementia significantly
improved agitation, aggression, and pain
Improved treatment of pain could help to reduce the unnecessary use of antipsychotics in people with dementia in
nursing homes
Standardised assessment and treatment of pain should be an integral part of the clinical management pathway for
people with dementia in nursing homes
Tables
Table 1| Baseline personal and clinical characteristics of nursing home residents assigned to intervention (stepwise protocol for treatment
of pain) or continued usual medical care. Values are numbers (percentages) of patients unless stated otherwise
Intervention group (n=175 residents) Control group (n=177 residents) Characteristics
33 27 No of clusters*
6 (2-10) 7 (3-10) Median (range) of patients per cluster
85 (65-101) 87 (67-104) Mean (range) age (years)
132 (75) 131 (74) Women
Prescribed drugs:
43 (25) 47 (27) Antipsychotics
80 (46) 88 (50) Anxiolytics or hypnotics
53 (30) 44 (25) Anti-dementia
35 (20) 32 (18) Opioid analgesics
75 (43) 71 (40) Peripheral analgesics
53 (39-126) 51 (39-114) Median (range) Cohen-Mansfield agitation inventory (scores 29-203)†
7 (0-20) 8 (0-20) Median (range) mini-mental state examination (scores 0-30)‡
6 (4-7) 6 (4-7) Median (range) functional assessment staging (scores 1-7)§
32 (1-101) 29 (0-97) Median (range) neuropsychiatric inventory—nursing home version (scores 1-144)¶
4.0 (0-10); 103 (59) 3.0 (0-10); 98 (55) Median (range) MOBID-2 pain scale (scores 0-10)**; pain ≥3
7.00 (0-19) 8.0 (0-20) Median (range) activities of daily living (scores 0-20)††
MOBID-2=mobilisation-observation-behaviour-intensity-dementia-2.
*Cluster defined as a single independent nursing home unit.
†Higher scores indicate more agitation (scores ≥39 usually accepted as clinically significant).
‡Higher scores indicate more cognitive impairment.
§Higher scores indicate more cognitive impairment.
¶Higher scores indicate more agitation.
**Higher scores indicate more pain (scores ≥3 accepted as clinically relevant).
††Higher scores indicate more activities of daily living.
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RESEARCHTable 2| Stepwise protocol for treatment of pain
No (%) of residents (n=175) Dosage Study treatment Pain treatment at baseline Step
120 (69)* Maximum dose 3 g/day Paracetamol (acetaminophen) No analgesics, or low dose of paracetamol 1
4 (2) 5 mg twice daily; maximum dose 10 mg
twice daily
Morphine Full dose of paracetamol or low dose
morphine
2
39 (22)† 5 µg/h, maximum dose 10 µg/h Buprenorphine transdermal patch Low dose buprenorphine or inability to
swallow
3
12 (7) 25 mg once daily; maximum dose 300
mg/day
Pregabaline Neuropathic pain 4
*In nine participants an existing low dosage was increased.
†Dosage was increased in eight participants.
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RESEARCHTable 3| Comparison of Cohen-Mansfield agitation inventory (CMAI) total score between control and intervention (stepwise protocol for
treatment of pain) groups using repeated measures analysis of covariance (ANCOVA)*
Intracluster
correlation
coefficient‡
Effect of intervention on CMAI total† Mean (SD) CMAI total score
Week P value Estimate (95% CI) Intervention group Control group
0.162 — — 56.5 (15.2), n=175 56.2 (16.1), n=177 0
0.261 0.022 −3.6 (−0.5 to −6.7) 52.0 (19.5), n=158 53.9 (17.0), n=161 2
0.231 0.012 −4.1 (−0.9 to −7.4) 49.4 (19.0), n=148 52.5 (16.3), n=160 4
0.226 <0.001 −7.0 (−3.7 to −10.3) 46.9 (18.7), n=147 52.8 (16.8), n=157 8
0.253 0.058 −3.2 (0.1 to −6.4) 50.3 (20.3), n=142 52.5 (16.0), n=152 12
*Baseline score as covariate and least squares weighted by number of patients within cluster; P value from multivariate test of intervention was 0.002, and cross
effect between week and intervention was <0.001.
†Variable estimate by week of effect of intervention on CMAI score from estimated model.
‡Proportion of total variance between clusters, and measured within framework of ANCOVA.
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RESEARCHTable 4| Comparison of neuropsychiatric inventory-nursing home version (NPI-NH) total score between control and intervention (stepwise
protocol for treatment of pain) groups using repeated measures analysis of covariance (ANCOVA)*
Intracluster
correlation
coefficient‡
Effect of intervention on NPI-NH total† Mean (SD) NPI-NH total
Week P value Estimate (95% CI) Intervention group Control group
0.106 — — 34.8 (21.9), n=175 31.4 (21.4), n=177 0
0.129 0.052 −2.9 (0.03 to −5.9) 26.5 (20.3), n=158 26.1 (19.2), n=161 2
0.116 0.001 −5.7 (−2.3 to −9.1) 23.4 (20.0), n=148 26.0 (20.1), n=160 4
0.157 <0.001 −9.0 (−5.5 to −12.6) 21.0 (19.3), n=147 26.9 (20.7), n=157 8
0.210 <0.001 −8.4 (−4.7 to −12.2) 23.0 (20.0), n=142 28.0 (21.1), n=152 12
*Baseline score as covariate and least squares weighted by number of patients within cluster; P values from multivariate test of intervention and cross effect
between week and intervention were both <0.001.
†Variable estimate by week of effect of intervention on NPI-NH from estimated model.
‡Proportion of total variance between clusters, and measured within framework of ANCOVA.
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RESEARCHTable 5| Comparison of mobilisation-observation-behaviour-intensity-dementia-2 (MOBID-2) pain scale total score between control and
intervention (stepwise protocol for treatment of pain) groups using repeated measures analysis of covariance (ANCOVA)*
Intracluster
correlation
coefficient‡
Effect of intervention on MOBID-2 total† Mean (SD) MOBID-2 total
Week P value Estimate (95% CI) Intervention group Control group
0.094 3.8 (2.7), n=164 3.7 (2.5), n=163 0
0.070 <0.001 −0.7 (−0.4 to −1.1) 2.9 (2.5), n=152 3.5 (2.4), n=159 2
0.059 <0.001 −0.8 (−0.4 to −1.2) 2.7 (2.2), n=146 3.3 (2.4), n=155 4
0.082 <0.001 −1.3 (−0.8 to −1.7) 2.3 (2.1), n=145 3.5 (2.6), n=154 8
0.139 0.001 −0.8 (−0.3 to −1.2) 2.9 (2.6), n=140 3.5 (2.5), n=151 12
*Baseline score as covariate and least squares weighted by number of patients within cluster; P value from multivariate test of intervention was <0.001, and cross
effect between week and intervention was 0.009.
†Variable estimate by week of effect of intervention on MOBID-2 from estimated model.
‡Proportion of total variance between clusters, and measured within framework of ANCOVA.
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RESEARCHFigures
Fig 1 Flow of participants through trial
Fig 2 Cohen-Mansfield agitation inventory scores, with 95% confidence intervals, over study period
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RESEARCH